Senate: Kaléo’s Naloxone Price Hike Cost Taxpayers Millions

Drug Industry Daily
A A
Kaléo’s massive, artificially inflated price hikes for its naloxone auto-injector Evzio have cost taxpayers more than $142 million over the past four years, says a new Senate report.

To View This Article:

Login

Subscribe To Drug Industry Daily